Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson’s Disease
- 16 October 2018
- journal article
- letter
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (3) , 255-260
Abstract
Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To advance toward the clinic, a spray-dried dispersion (SDD) formulation of VU2957 was developed to support IND-enabling toxicology studies. Based on its overall profile, VU2957 was evaluated as a preclinical development candidate for the treatment of Parkinson’s disease.Keywords
Funding Information
- National Institutes of Health
This publication has 31 references indexed in Scilit:
- The Metabotropic Glutamate Receptor 4-Positive Allosteric Modulator VU0364770 Produces Efficacy Alone and in Combination with l-DOPA or an Adenosine 2A Antagonist in Preclinical Rodent Models of Parkinson’s DiseaseThe Journal of Pharmacology and Experimental Therapeutics, 2012
- Recent Progress on the Identification of Metabotropic Glutamate 4 Receptor Ligands and Their Potential Utility as CNS TherapeuticsACS Chemical Neuroscience, 2011
- A Virtual Screening Hit Reveals New Possibilities for Developing Group III Metabotropic Glutamate Receptor AgonistsJournal of Medicinal Chemistry, 2010
- Mglur4-Positive Allosteric Modulation as Potential Treatment for Parkinson’s DiseaseFuture Medicinal Chemistry, 2009
- Synthesis and Evaluation of a Series of Heterobiarylamides That Are Centrally Penetrant Metabotropic Glutamate Receptor 4 (mGluR4) Positive Allosteric Modulators (PAMs)Journal of Medicinal Chemistry, 2009
- Preventing and controlling dyskinesia in Parkinson's disease-A view of current knowledge and future opportunitiesMovement Disorders, 2008
- Functional organization of the basal ganglia: Therapeutic implications for Parkinson's diseaseMovement Disorders, 2008
- Pharmacological Activation of mGlu4 Metabotropic Glutamate Receptors Reduces Nigrostriatal Degeneration in Mice Treated with 1-Methyl-4-Phenyl-1,2,3,6-TetrahydropyridineJournal of Neuroscience, 2006
- Metabotropic Glutamate Receptor Subtypes as Targets for Neuroprotective DrugsJournal of Cerebral Blood Flow & Metabolism, 2001
- PHARMACOLOGY AND FUNCTIONS OF METABOTROPIC GLUTAMATE RECEPTORSAnnual Review of Pharmacology and Toxicology, 1997